Opioid treatment and "Long-QT Syndrome (LQTS)": A critical review of the literature

Heroin Addiction and Related Clinical Problems

Volumn 11, Issue 4, 2009, Pages 21-28

  Pacini, Matteo ^a   Maremmani, Angelo G I ^b   Dell'Osso, Liliana ^c   Maremmani, Icro ^a,b,c  

^a G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^b AU CNS   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Long QT syndrome; Opioid treatment; Review

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE;

CHRONIC PAIN; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEROIN DEPENDENCE; HUMAN; LONG QT SYNDROME; MAINTENANCE THERAPY; MORTALITY; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; TORSADE DES POINTES;

EID: 74549153367     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. AIFA (2003): Farmaci e sindrome del QT lungo. Bollettino di Informazione sui Farmaci. X:(5-6) 179-184.
2. Anchersen K., Clausen T., Gossop M., Hansteen V., Waal H. (2009): Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 104:(6) 993-999.
3. Arizona Cert (2009): QT Drug List. Available at http://www.azcert.org/ medical-pros/drug-lists/druglists.cfm. Accessed June 2009,
4. Athanasos P., Farquharson A. L., Compton P., Psaltis P., Hay J. (2008): Electrocardiogram characteristics of methadone and buprenorphine maintained subjects. J Addict Dis. 27:(3) 31-35.
5. Baker J. R., Best A. M., Pade P. A., Mccance-Katz E. F. (2006): Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother. 40:(3) 392-396.
6. Bazett H. C. (1920): An analysis of time relations of electrocardiograms. Heart. 7 353-367.
7. Bednar M. M., Harrigan E. P., Anziano R. J., Camm A. J., Ruskin J. N. (2001): The QT interval. Prog Cardiovasc Dis. 43:(5 Suppl 1) 1-45.
8. Clancy C. E., Kurokawa J., Tateyama M., Wehrens X. H. T., Kass R. S. (2003): K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annu Rev Pharmacol Toxicol. 43 441-461.
9. Clancy C. E., Rudy Y. (2001): Cellular consequences of HERG mutations in the long QT syndrome: precursors to sudden cardiac death. Cardiovasc Res. 50 301-313.
10. Crouch M. A., Limon L., Cassano A. T. (2003): Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy. 23:(7) 881-908.
11. Cruciani R. A., Sekine R., Homel P., Lussier D., Yap Y., Suzuki Y., Schweitzer P., Yancovitz S. R., Lapin J. A., Shaiova L., Sheu R. G., Portenoy R. K. (2005): Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage. 29:(4) 385-391.
12. Csat (2004): Methadone-Associated Morthality: Background Briefing Report. Center for Substance Abuse Treatment, Rockville, Md.
13. De Bels D., Staroukine M., Devriendt J. (2003): Torsades de pointes due to methadone. Ann Intern Med. 139:(2) E156.
14. De Ponti F., Poluzzi E., Montanaro N. (2000): QT interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol. 56 1-18.
15. Decerf J. A., Gressens B., Brohet C., Liolios A., Hantson P. (2004): Can methadone prolong the QT interval? Intensive Care Med. 30:(8) 1690-1691.
16. Drici M. D., Barhanin J. (2000): Cardiac K+ channels and drug-acquired long QT syndrome. Therapie. 55:(1) 185-193.
17. Eap C. B., Bertschy G., Baumann P., Finkbeiner T., Gastpar M., Scherbaum N. (1998): High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry. 55:(1) 89-90.
18. Ebert S. N., Liu X. K., Woosley R. L. (1998): Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 7:(5) 547-557.
19. Ehret G. B., Voide C., Gex-Fabry M., Chabert J., Shah D., Broers B., Piguet V., Musset T., Gaspoz J. M., Perrier A., Dayer P., Desmeules J. A. (2006): Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 166:(12) 1280-1287.
20. o 8776/01. EMEA, London.
21. Esses J. L., Rosman J., Do L. T., Schweitzer P., Hanon S. (2008): Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes. J Interv Card Electrophysiol. 23:(2) 117-119.
22. Fanoe S., Hvidt C., Ege P., Jensen G. B. (2007): Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 93:(9) 1051-1055.
23. Fonseca F., Marti-Almor J., Pastor A., Cladellas M., Farre M., De La Torre R., Torrens M. (2009): Prevalence of long QTc interval in methadone maintenance patients. Drug Alcohol Depend. 99:(1-3) 327-332.
24. Fredheim O. M., Borchgrevink P. C., Hegrenaes L., Kaasa S., Dale O., Klepstad P. (2006): Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: A prospective 9-month follow-up study. J Pain Symptom Manage. 32:(2) 180-185.
25. Fridericia L. S. (1920): Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand 53:(469-486).
26. Garson A., Jr. (1993): How to measure the QT interval - what is normal? Am J Cardiol. 72:(6) 14B-16B.
27. Gil M., Sala M., Anguera I., Chapinal O., Cervantes M., Guma J. R., Segura F. (2003): QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol. 92:(8) 995-997.
28. Goodnick P. J., Jerry J., Parra F. (2002): Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother. 3:(5) 479-498.
29. Hser Y., Hoffman V., Grella C., Anglin M. D. (2001): A 33-year follow-up of narcotic addicts. Arch Gen Psychiatry. 58 503-508.
30. Huber A., Ling W., Fradis J., Charuvastra V. C. (2001): Comparison of the effects of methadone and LAAM on the EKG. Drug Alcohol Depend. 63 S70.
31. Indik J. H., Pearson E. C., Fried K., Woosley R. L. (2006): Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm. 3:(9) 1003-1007.
32. Joseph H., Stancliff S., Langrod J. (2000): Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 67:(5-6) 347-364.
33. Justo D. (2006): Methadone-induced long QT syndrome vs methadone-induced torsades de pointes. Arch Intern Med. 166:(20) 2288; author reply 2289-2290.
34. Katchman A. N., Mcgroary K. A., Kilborn M. J., Kornick C. A., Manfredi P. L., Woosley R. L., S.N. E. (2002): Influence of opioid agonists on cardiac human ether-a-go-go related gene K+ current. J Pharmacol Exp Ther. 303 688-694.
35. Keating M. T., Sanguinetti M. C. (2001): Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 104:(4) 569-580.
36. Kornick C. A., Kilborn M. J., Santiago-Palma J., Schulman G., Thaler H. T., Keefe D. L., Katchman A. N., Pezzullo J. C., Ebert S. N., Woosley R. L., Payne R., Manfredi P. L. (2003): QTc interval prolongation associated with intravenous methadone. Pain. 105:(3) 499-506.
37. Krantz M. J., Garcia J. A., Mehler P. S. (2005): Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy. 25:(4) 611-614.
38. Krantz M. J., Kutinsky I. B., Robertson A. D., Mehler P. S. (2003): Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy. 23:(6) 802-805.
39. Krantz M. J., Lewkowicz L., Hays H., Woodroffe M. A., Robertson A. D., Mehler P. S. (2002): Torsade de pointes associated with very-high-dose methadone. Ann Intern Med, 137 501-504.
40. Krantz M. J., Lowery C. M., Martell B. A., Gourevitch M. N., Arnsten J. H. (2005): Effects of methadone on QT-interval dispersion. Pharmacotherapy. 25:(11) 1523-1529.
41. Lange R. A., Hillis L. D. (2001): Cardiovascular complications of cocaine use. N Engl J Med. 345:(5) 351-358.
42. Leavitt S. B., Shinderman M., Maxwell S., Eap C. B., Paris P. (2000): When "enough" is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med. 67:(5-6) 404-411.
43. Lin C., Somberg T., Molnar J., Somberg J. (2009): The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology. 113:(1) 59-65.
44. Lipski J., Stimmel B., Donoso E. (1973): The effect of heroin and multiple drug abuse on the electrocardiogram. Am Heart J. 86:(5) 663-668.
45. Makkar R. R., Fromm B. S., Steinman R. T., Meissner M. D., Lehmann M. H. (1993): Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Jama. 270:(21) 2590-2597.
46. Maremmani I., Pacini M., Cesaroni C., Lovrecic M., Perugi G., Tagliamonte A. (2005): QTc interval prolungation in patients on long-term methadone maintenance therapy. Eur Addict Res. 11:(1) 44-49.
47. Martell B. A., Arnsten J. H., Krantz M. J., Gourevitch M. N. (2005): Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 95:(7) 915-918.
48. Mayet S. (2009): Available at http://www.apsad.org.au/papers/Tuesday/tue- mr1-1418-mayet.pdf. Accessed June 2009,
49. Meyer J. S., Mehdirad A., Salem B. I., Kulikowska A., Kulikowski P. (2003): Sudden arrhythmia death syndrome: importance of the long QT syndrome. Am Fam Physician. 68:(3) 483-488.
50. Mokwe E. O., Ositadinma O. (2003): Torsade de pointes due to methadone. Ann Intern Med. 139:(4) W64.
51. Montanez A., Ruskin J. N., Hebert P. R., Lamas G. A., Hennekens C. H. (2004): Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med. 164:(9) 943-948.
52. Morganroth J. (1993): Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. Am J Cardiol. 72:(6) 10B-13B.
53. Moss A. J. (2003): Long QT Syndrome. Jama. 289:(16) 2041-2044.
54. Novick D. M., Richman B. L., Friedman J. M., Friedman J. E., Fried C., Wilson J. P., Townley A., Kreek M. J. (1993): The medical status of methadone maintained patients in treatment for 11-18 years. Drug Alcohol Depend. 33 235-245.
55. O'leary M. E. (2002): Inhibition of HERG potassium channels by cocaethylene: a metabolite of cocaine and ethanol. Cardiovasc Res. 53:(1) 59-67.
56. Pearson E. C., Woosley R. L. (2005): QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 14:(11) 747-753.
57. Peles E., Bodner G., Kreek M. J., Rados V., Adelson M. (2007): Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction. 102:(2) 289-300.
58. Piguet V., Desmeules J., Ehret G., Stoller R., Dayer P. (2004): QT interval prolongation in patients on methadone with concomitant drugs. J Clin Psychopharmacol. 24:(4) 446-448.
59. Priori S. G., Schwartz P. J., Napolitano C., Bloise R., Ronchetti E., Grillo M., Vicentini A., Spazzolini C., Nastoli J., Bottelli G., Folli R., Cappelletti D. (2003): Risk stratification in the long-QT syndrome. N Engl J Med. 348:(19) 1866-1874.
60. Reilly J. G., Ayis S. A., Ferrier I. N., Jones S. J., Thomas S. H. L. (2000): QT interval abnormalities and psychotic drug therapy in psychiatric patients. Lancet. 355 1048-1052.
61. Robbins J., Nelson J. C., Rautaharju P. M., Gottdiener J. S. (2003): The association between the length of the QT interval and mortality in the cardiovascular health study. Am J Med. 115:(9) 689-694.
62. Roden D. M. (2004): Drug-induced prolongation of the QT interval. N Engl J Med. 350:(10) 1013-1022.
63. Sagie A., Larson M. G., Goldberg R. J., Bengtson J. R., Levy D. (1992): An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol. 70:(7) 797-801.
64. Sala M., Anguera I., Cervantes M. (2003): Torsade de pointes due to methadone. Ann Intern Med. 139:(4) W64.
65. Sticherling C., Schaer B. A., Ammann P., Maeder M., Osswald S. (2005): Methadone-induced Torsade de pointes tachycardias. Swiss Med Wkly. 135:(19-20) 282-285.
66. Tamargo J. (2000): Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol. 83:(1) 1-19.
67. Towbin J. A., Vatta M. (2001): Molecular biology and the prolonged QT syndromes. Am J Med. 110:(5) 385-398.
68. Vincent G. M. (2000): Long QT syndrome. Cardiol Clin. 18:(2) 309-325.
69. Vincent G. M., Timothy K., Fox J., Zhang L. (1999): The inherited long QT syndrome: from ion channel to bedside. Cardiol Rev. 7:(1) 44-55.
70. Viskin S. (2000): Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol. 11:(5) 593-600.
71. Walker P. W., Klein D., Kasza L. (2003): High dose methadone and ventricular arrhythmias: a report of three cases. Pain. 103:(3) 321-324.
72. Wedam E. F., Bigelow G. E., Johnson R. E., Nuzzo P. A., Haigney M. C. (2007): QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 167:(22) 2469-2475.
73. Welch R., Chue P. (2000): Antipsychotic agents and QT changes. J Psychiatry Neurosci. 25:(2) 154-160.
74. Yap Y. G., Camm A. J. (2003): Drug induced QT prolongation and torsades de pointes. Heart. 89:(11) 1363-1372.